Inhibition of the formation of advanced glycation end products by thymoquinone.

The inhibitory activity of thymoquinone, a major quinone from black seeds (Nigella sativa) against the formation of advanced glycation end products was studied using the hemoglobin-δ-gluconolactone, human serum albumin-glucose, and the N-acetyl-glycyl-lysine methyl ester-ribose assays. A comparison was made with the inhibitory activity of aminoguanidine. The cytotoxicity of thymoquinone was studied by the release of lactate dehydrogenase from platelets and the levels of plasma thiols. At 20µM, thymoquinone inhibited 39% of hemoglobin glycation, 82% of post-Amadori glycation products, reduced methyglyoxal-mediated human serum albumin glycation by 68%, inhibited 78% of late glycation end products. Aminoguanidine at 10mM was less effective than thymoquinone. The IC50 for thymoquinone and aminoguanidine were 7.2µM and 1.25mM, respectively. Thymoquinone at 20-50µM was not toxic to platelet lactate dehydrogenase and plasma thiols. The potential of thymoquinone in food applications is discussed.

In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.

Ceramide methylaminoethylphosphonate (CMAEPn) was isolated from eastern oyster ( Crassostrea virginica ) and screened against in vitro and in vivo angiogenesis and against MCF-7 and MDA-MB-435s breast cancer cell lines. In vitro angiogenesis was evaluated by the vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) tube formation assay. MCF-7 and MDA-MB-435s cell viability was evaluated by the CellTiter 96 AQ(ueous) One Solution Cell Proliferation assay. Apoptosis was evaluated by the caspase-9 assay, autophagy by acridine orange staining and beclin-1 level. Our study indicates that CMAEPn at 50 microM inhibited VEGF-induced tube formation by HUVEC. The viability of MCF-7 and MDA-MB-435s breast cancer cells exposed to 125 microM CMAEPn for 48 h was reduced to 76 and 85%, respectively. The viability of MCF-7 and MDA-MB-435s cells exposed to 250 microM CMAEPn for 48 h under the same conditions was reduced to 38 and 45%, respectively. CMAEPn at 125 microM inhibited VEGF-induced MDA-MB-435s cell migration and invasion. CMAEPn at 125 microM also decreased VEGF, EGF levels in the conditioned media, PI3K, IkappaB phosphorylation and degradation in the cytoplasmic extracts, and NFkappaB nuclear translocation. Both acridine orange staining and beclin-1 indicated autophagic cell death in MCF-7 and MDA-MB-435s cells, respectively. In vivo, CMAEPn at 30 mg/kg body weight inhibited bFGF-induced angiogenesis and caused a 57% reduction in hemoglobin levels in the matrigel plug assay within 7 days. This is the first report on CMAEPn-inhibited angiogenesis both in vitro and in vivo.